GALWAY, Ireland, Oct. 22, 2025 /PRNewswire/ -- Neurent Medical, a leader in non-surgical treatments for chronic rhinitis, today announced that UnitedHealthcare's Medicare Advantage policy has removed ...
Neurent Medical, a company developing non-surgical interventions to treat chronic inflammatory sinonasal diseases, has released positive six-month results from the PARAGON clinical study in Ear, Nose ...
76% of participants achieved the responder rate (≥30% reduction in rTNSS). 91% achieved the minimum clinically important difference (MCID) of ≥1 point reduction in rTNSS. All 4 rTNSS subscores ...
Neurent Medical has closed an oversubscribed Series C financing round, raising €62.5m ($74m) to expand commercial activities for the NEUROMARK system targeting chronic rhinitis, generate additional ...
GALWAY, Ireland--(BUSINESS WIRE)--Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, today announced three-month data from ...
GALWAY, Ireland, Feb. 24, 2026 /PRNewswire/ -- Neurent Medical, a leader in non-surgical treatments for chronic rhinitis, today announced the publication of positive results from its randomized ...
NEUROMARK received new Category I CPT code and support from AAO position statement Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sino-nasal ...
Effective September 15, CPT 31242 is no longer considered experimental, clearing an important barrier for ENT physicians treating chronic rhinitis. GALWAY, Ireland, June 30, 2025 /PRNewswire/ -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results